$ENTA
ENANTA PHARMACEUTICALS INC

2020 Q2 Form 10-K Financial Statement

#000156459020055233 Filed on November 25, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2020 Q1 2019 Q4
Revenue $18.65M $27.62M $52.57M
YoY Change -57.96% -30.31% -24.78%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.820M $6.880M $6.920M
YoY Change 10.89% 1.47% -3.22%
% of Gross Profit
Research & Development $34.68M $32.61M $32.78M
YoY Change 0.64% -4.54% -6.02%
% of Gross Profit
Depreciation & Amortization $920.0K $920.0K $900.0K
YoY Change 3.37% 15.0% 32.35%
% of Gross Profit
Operating Expenses $41.51M $32.61M $32.78M
YoY Change 2.22% -20.35% -6.02%
Operating Profit -$11.88M $12.87M
YoY Change 810.66% -53.79%
Interest Expense $1.450M $1.950M $2.080M
YoY Change -40.08% -13.14% 10.34%
% of Operating Profit 16.16%
Other Income/Expense, Net $1.445M $1.950M $2.076M
YoY Change -40.17% -13.14% 10.13%
Pretax Income -$21.41M -$9.925M $14.95M
YoY Change -447.0% -1154.73% -49.73%
Income Tax -$7.142M -$3.920M $1.504M
% Of Pretax Income 10.06%
Net Earnings -$14.27M -$6.005M $13.44M
YoY Change -302.74% -244.87% -48.32%
Net Earnings / Revenue -76.48% -21.74% 25.57%
Basic Earnings Per Share -$0.71 -$0.30 $0.68
Diluted Earnings Per Share -$0.71 -$0.30 $0.65
COMMON SHARES
Basic Shares Outstanding 20.02M 19.92M 19.75M
Diluted Shares Outstanding 20.02M 19.92M 20.77M

Balance Sheet

Concept 2020 Q2 2020 Q1 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $370.0M $355.3M $373.8M
YoY Change -4.94% -4.02% 8.1%
Cash & Equivalents $100.5M $74.30M $27.56M
Short-Term Investments $270.1M $280.9M $346.2M
Other Short-Term Assets $24.70M $19.80M $14.20M
YoY Change 40.34% 40.43% 86.84%
Inventory
Prepaid Expenses
Receivables $18.70M $27.60M $52.57M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $413.4M $402.7M $440.5M
YoY Change -8.39% -4.98% 4.06%
LONG-TERM ASSETS
Property, Plant & Equipment $16.90M $17.60M $10.41M
YoY Change 48.6% 53.04% 9.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $65.40M $80.10M $40.90M
YoY Change 385.45% 255.65%
Other Assets $16.00M $13.10M $92.00K
YoY Change 17291.3% 33.67% 0.0%
Total Long-Term Assets $98.30M $110.8M $70.47M
YoY Change 342.35% 193.12% 128.12%
TOTAL ASSETS
Total Short-Term Assets $413.4M $402.7M $440.5M
Total Long-Term Assets $98.30M $110.8M $70.47M
Total Assets $511.7M $513.5M $511.0M
YoY Change 8.07% 11.24% 12.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.100M $5.900M $6.596M
YoY Change -6.21% -33.71% 17.79%
Accrued Expenses $13.58M $9.807M $9.411M
YoY Change -3.01% -15.46% -15.97%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $23.90M $19.50M $19.14M
YoY Change 16.58% -4.88% -15.31%
LONG-TERM LIABILITIES
Long-Term Debt $1.600M $1.600M $1.600M
YoY Change -15.79% -15.79% -15.79%
Other Long-Term Liabilities $1.058M $1.036M $1.933M
YoY Change -67.53% -68.11% -38.06%
Total Long-Term Liabilities $1.058M $1.036M $1.933M
YoY Change -67.53% -68.11% -38.06%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.90M $19.50M $19.14M
Total Long-Term Liabilities $1.058M $1.036M $1.933M
Total Liabilities $31.10M $27.50M $28.69M
YoY Change 22.5% 8.4% 4.77%
SHAREHOLDERS EQUITY
Retained Earnings $177.2M
YoY Change 23.59%
Common Stock $314.2M
YoY Change 8.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $480.6M $486.0M $482.3M
YoY Change
Total Liabilities & Shareholders Equity $511.7M $513.5M $511.0M
YoY Change 8.07% 11.25% 12.5%

Cashflow Statement

Concept 2020 Q2 2020 Q1 2019 Q4
OPERATING ACTIVITIES
Net Income -$14.27M -$6.005M $13.44M
YoY Change -302.74% -244.87% -48.32%
Depreciation, Depletion And Amortization $920.0K $920.0K $900.0K
YoY Change 3.37% 15.0% 32.35%
Cash From Operating Activities -$4.490M $14.68M $12.36M
YoY Change -277.47% -51.21% -59.14%
INVESTING ACTIVITIES
Capital Expenditures -$280.0K -$350.0K $488.0K
YoY Change -87.44% -86.06% 27.08%
Acquisitions
YoY Change
Other Investing Activities $27.05M $28.10M -$36.71M
YoY Change -314.34% 633.68% 78.64%
Cash From Investing Activities $26.78M $27.75M -$37.20M
YoY Change -280.34% 2002.27% 77.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.230M 4.350M 1.166M
YoY Change 559.18% 1573.08% 2.28%
NET CHANGE
Cash From Operating Activities -4.490M 14.68M 12.36M
Cash From Investing Activities 26.78M 27.75M -37.20M
Cash From Financing Activities 3.230M 4.350M 1.166M
Net Change In Cash 25.52M 46.78M -23.67M
YoY Change -315.72% 47.71% -326.24%
FREE CASH FLOW
Cash From Operating Activities -$4.490M $14.68M $12.36M
Capital Expenditures -$280.0K -$350.0K $488.0K
Free Cash Flow -$4.210M $15.03M $11.88M
YoY Change -188.45% -53.9% -60.24%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P18M
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y7D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y18D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y18D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y6M
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y4M24D
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y2M12D
CY2019 enta Effective Income Tax Rate Reconciliation Change In Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInValuationAllowance
CY2018 enta Effective Income Tax Rate Reconciliation Change In Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInValuationAllowance
CY2019 enta Effective Income Tax Rate Reconciliation Change In Deferred Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxRate
CY2018 enta Effective Income Tax Rate Reconciliation Change In Deferred Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxRate
CY2020 enta Effective Income Tax Rate Reconciliation Foreign Derived Intangible Income Percent
EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent
CY2018 enta Effective Income Tax Rate Reconciliation Foreign Derived Intangible Income Percent
EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent
CY2020 enta Effective Income Tax Rate Reconciliation Tax Cut And Jobs Act Of2017 Percent
EffectiveIncomeTaxRateReconciliationTaxCutAndJobsActOf2017Percent
CY2019 enta Effective Income Tax Rate Reconciliation Tax Cut And Jobs Act Of2017 Percent
EffectiveIncomeTaxRateReconciliationTaxCutAndJobsActOf2017Percent
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity File Number
EntityFileNumber
001-35839
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3205099
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
500 Arsenal Street
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
CY2020 dei City Area Code
CityAreaCode
617
CY2020 dei Local Phone Number
LocalPhoneNumber
607-0800
CY2020 dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
608000
CY2020Q3 us-gaap Assets
Assets
486132000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5737000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14159000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4261000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
24157000
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
22609000
CY2020Q1 dei Entity Public Float
EntityPublicFloat
753821750
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20078942
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
462492000
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10481000
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020 enta Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19703000
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19703000
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
197000
CY2019Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
298409000
CY2019Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
146000
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
163740000
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51230000
CY2019Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
284006000
CY2019Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
51313000
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
15299000
CY2019Q3 us-gaap Assets Current
AssetsCurrent
401848000
CY2019Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
65013000
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10927000
CY2020Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
345000
CY2019Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
11341000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7020000
CY2019Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
608000
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
92000
CY2019Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
92000
CY2019Q3 us-gaap Assets
Assets
489829000
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6689000
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15920000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3838000
CY2019Q3 enta Non Convertible Preferred Stock Liabilities
NonConvertiblePreferredStockLiabilities
1628000
CY2019Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3100000
CY2019Q3 us-gaap Liabilities
Liabilities
27337000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
205197000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
206625000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
46383000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
393679000
CY2019 enta Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
6848000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19226000
CY2020 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
149000
CY2018 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
-59000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-826000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
46383000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
71956000
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.37
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.74
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.21
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.48
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19584000
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19255000
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20968000
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20650000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
46383000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
544000
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-286000
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-286000
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
301676000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15845000
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-286000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
71956000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
544000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1317000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1843000
CY2020 enta Premium On Marketable Securities
PremiumOnMarketableSecurities
3575000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-304000
CY2020 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
149000
CY2020 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
51000
CY2020 enta Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-3184000
CY2020 enta Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3535000
CY2018 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
564000
CY2018 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
92000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
29220000
CY2018 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
293103000
CY2018 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
260682000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2981000
CY2019 us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
0
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35402000
CY2018 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
6244000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8983000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
35901000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
51838000
CY2020 us-gaap Income Taxes Paid
IncomeTaxesPaid
105000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, <span style="Background-color:#FFFFFF;">management’s judgments with respect to its revenue arrangements; valuation of Series 1 nonconvertible preferred stock and stock-based awards; the accrual of research and development expenses, and the accounting for income taxes, including uncertain tax positions and the valuation of net deferred tax assets. </span>Estimates are periodically reviewed in light of changes in circumstances, facts and experience. <span style="Background-color:#FFFFFF;">The future developments of the COVID-19 pandemic also may directly or indirectly impact the Company’s business include quarantines, border closures, increased border controls, travel restrictions, shelter-in-place orders and shutdowns, business closures, cancellations of public gatherings and other measures. The Company has made estimates of the impact of COVID-19 in the Company’s consolidated financial statements as of September 30, 2020. Actual results could differ from the Company’s estimates.</span></p>
CY2020 us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
0
CY2019Q3 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
254000
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk and of Significant Customers and Suppliers </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and accounts receivable. The Company has all cash and investment balances at one accredited financial institution, including cash in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has historically generated the majority of its revenue from its collaborative research and license agreements. As of September 30, 2020 and 2019, accounts receivable consisted of amounts due from the Company’s principal collaborator (see Note 7). </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is completely dependent on third-party manufacturers for product supply for preclinical and clinical research activities. The Company relies and expects to continue to rely exclusively on several manufacturers to supply the Company with its drug supply requirements related to these activities. These research programs would be adversely affected by a significant interruption in the supply from these third-party manufacturers. </p>
CY2018 us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
0
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
608000
CY2019Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
608000
CY2019Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
759000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
7151000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8622000
CY2019Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
393588000
CY2019Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1628000
CY2020 enta Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
14000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
332152000
CY2019Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
348876000
CY2019Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
230000
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
330923000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
612000
CY2019Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
87000
CY2019Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
349019000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
32634000
CY2019Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
65013000
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1243000
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
24270000
CY2019Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
23108000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15674000
CY2019Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12181000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8596000
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10927000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3644000
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3258000
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2518000
CY2020Q3 enta Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
5407000
CY2019Q3 enta Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
6936000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4777000
CY2019Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3894000
CY2020Q3 enta Accrued Liabilities Manufacturing
AccruedLiabilitiesManufacturing
2885000
CY2019Q3 enta Accrued Liabilities Manufacturing
AccruedLiabilitiesManufacturing
3447000
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
478000
CY2019Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
884000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14159000
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15920000
CY2020Q3 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
788000
CY2019Q3 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
1746000
CY2019Q3 us-gaap Accrued Rent Noncurrent
AccruedRentNoncurrent
900000
CY2019Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
200000
CY2020Q3 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
290000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
21860000
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
59.85
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
327000
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
32.05
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
198000
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
71.66
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3262000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
49.82
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.55
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.57
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2967000
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
46.54
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
57336000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
820000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3262000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
49.82
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
21860000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2156000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
42.56
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
21387000
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1078000
CY2019Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3100000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q3 us-gaap Preferred Stock Share Subscriptions
PreferredStockShareSubscriptions
3000000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
1221000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0141
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0276
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0229
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.53
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
7850000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
13855000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
14180000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10481000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6848000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6243000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19575000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19226000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15845000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19575000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19226000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15845000
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
38894000
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M24D
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-36168000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
46383000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
71956000
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19940000
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19584000
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19255000
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.81
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.37
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.74
CY2018 us-gaap Net Income Loss
NetIncomeLoss
71956000
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19255000
CY2019 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1384000
CY2018 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1395000
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19940000
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20968000
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20650000
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.81
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0650
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.21
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.48
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3502000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
843000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
295000
CY2020 enta Number Of Leases
NumberOfLeases
2
CY2020 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
two options to extend the lease term for an additional three years each.
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
3776000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
2338000
CY2020 us-gaap Lease Cost
LeaseCost
6114000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
4126000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3053000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4654000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2936000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
608000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
519000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8717000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
618000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
8099000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4261000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3838000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
8099000
CY2019Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2728000
CY2019Q3 enta Finance Leases Future Minimum Payments Due Current
FinanceLeasesFutureMinimumPaymentsDueCurrent
93000
CY2019Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2803000
CY2019Q3 enta Finance Leases Future Minimum Payments Due In Two Years
FinanceLeasesFutureMinimumPaymentsDueInTwoYears
101000
CY2019Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2684000
CY2019Q3 enta Finance Leases Future Minimum Payments Due In Three Years
FinanceLeasesFutureMinimumPaymentsDueInThreeYears
99000
CY2019Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
608000
CY2019Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
519000
CY2019Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
9342000
CY2019Q3 enta Finance Leases Future Minimum Payments Due
FinanceLeasesFutureMinimumPaymentsDue
293000
CY2020Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
608000
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
608000
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-8491000
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
1841000
CY2018 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
16449000
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-941000
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
372000
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2858000
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
8916000
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-2431000
CY2018 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
2245000
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
1665000
CY2019 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-608000
CY2018 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-387000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1149000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-826000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
21165000
CY2020 enta Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate1
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate1
-0.21
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.245
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.028
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.018
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.026
CY2020 enta Effective Income Tax Rate Reconciliation Change In Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInValuationAllowance
0.521
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.133
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.128
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.052
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.028
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.067
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.028
CY2020 enta Effective Income Tax Rate Reconciliation Change In Deferred Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxRate
-0.102
CY2019 enta Effective Income Tax Rate Reconciliation Foreign Derived Intangible Income Percent
EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent
-0.032
CY2018 enta Effective Income Tax Rate Reconciliation Tax Cut And Jobs Act Of2017 Percent
EffectiveIncomeTaxRateReconciliationTaxCutAndJobsActOf2017Percent
0.042
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.043
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.019
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.006
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.033
CY2019Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
821000
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.018
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.227
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-18259000
CY2020Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
18259000
CY2020Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
11071000
CY2019Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
9901000
CY2020Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
6574000
CY2019Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
763000
CY2020Q3 enta Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
2468000
CY2020Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
1598000
CY2020Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
861000
CY2020Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
245000
CY2019Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
150000
CY2020Q3 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
444000
CY2019Q3 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
915000
CY2020Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
23261000
CY2019Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
12550000
CY2020Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
18259000
CY2020Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
5002000
CY2019Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
12550000
CY2020Q3 enta Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
2221000
CY2020Q3 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1650000
CY2019Q3 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1027000
CY2020Q3 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
364000
CY2019Q3 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
148000
CY2020Q3 us-gaap Deferred Tax Liabilities Other Comprehensive Income
DeferredTaxLiabilitiesOtherComprehensiveIncome
422000
CY2019Q3 us-gaap Deferred Tax Liabilities Other Comprehensive Income
DeferredTaxLiabilitiesOtherComprehensiveIncome
34000
CY2020Q3 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
4657000
CY2019Q3 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1209000
CY2020Q3 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
345000
CY2019Q3 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
11341000
CY2020 enta Research And Development Tax Credit Carry Forward Expiration Year
ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear
2039
CY2020Q3 enta Deferred Tax Assets Liabilities Gross
DeferredTaxAssetsLiabilitiesGross
18604000
CY2020 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
11071000
CY2020Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
18259000
CY2020 us-gaap Risks And Uncertainties In Entitys Business
RisksAndUncertaintiesInEntitysBusiness
In response to the COVID-19 pandemic, the CARES Act was signed into law in March 2020. The CARES Act lifts certain deduction limitations originally imposed by the Tax Cuts and Jobs Act of 2017 (the “Tax Act”). Under the CARES Act, the Company is permitted to carryback net operating losses for up to five years for losses generated in fiscal 2018 through fiscal 2021. Net operating loss carrybacks were previously prohibited under the Tax Act. The CARES Act also eliminates the 80% of taxable income limitations by allowing corporate entities to fully utilize net operating loss carryforwards to offset taxable income in fiscal years 2018, 2019 or 2020. In addition, the CARES Act makes qualified improvement property eligible for 15-year cost-recovery and 100% bonus depreciation. The enactment of the CARES Act resulted in a $8,581 income tax benefit related to a federal net operating loss carryback at the previously enacted 35% rate in the Company’s consolidated financial statements during the year ended September 30, 2020.
CY2020 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
8581000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Percent
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
0.35
CY2020Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
103000
CY2019Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
244000
CY2019Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1650000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1679000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
11000
us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
156000
CY2020 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
719000
us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
87000
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
98000
us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
98000
CY2020Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
844000
CY2019Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1650000
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1190000
CY2019 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1068000
CY2018 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
852000
CY2019Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52570000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27619000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18653000
CY2019Q4 us-gaap Costs And Expenses
CostsAndExpenses
39699000
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
39494000
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
41505000
CY2019Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2076000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1950000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1445000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2415000
CY2019Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1504000
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3920000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7142000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
13443000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-6005000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-14265000
CY2019Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.68
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
CY2019Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.65
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
CY2018Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
69886000
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
39631000
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
44367000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
51313000
CY2018Q4 us-gaap Costs And Expenses
CostsAndExpenses
42030000
CY2019Q1 us-gaap Costs And Expenses
CostsAndExpenses
40935000
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
40612000
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
44882000
CY2018Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1885000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2245000
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2274000
CY2018Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3730000
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3204000
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-866000
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-486000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
26011000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
4145000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
7036000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
9191000
CY2018Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.34
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.21
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.36
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.47
CY2018Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.25
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.20
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.33
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.44

Files In Submission

Name View Source Status
0001564590-20-055233-index-headers.html Edgar Link pending
0001564590-20-055233-index.html Edgar Link pending
0001564590-20-055233.txt Edgar Link pending
0001564590-20-055233-xbrl.zip Edgar Link pending
enta-10k_20200930.htm Edgar Link pending
enta-10k_20200930_htm.xml Edgar Link completed
enta-20200930.xsd Edgar Link pending
enta-20200930_cal.xml Edgar Link unprocessable
enta-20200930_def.xml Edgar Link unprocessable
enta-20200930_lab.xml Edgar Link unprocessable
enta-20200930_pre.xml Edgar Link unprocessable
enta-ex1027_466.htm Edgar Link pending
enta-ex211_9.htm Edgar Link pending
enta-ex231_6.htm Edgar Link pending
enta-ex311_10.htm Edgar Link pending
enta-ex312_11.htm Edgar Link pending
enta-ex321_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gcxqceod4dzq000001.jpg Edgar Link pending
gcxqceod4dzq000002.jpg Edgar Link pending
gcxqceod4dzq000003.jpg Edgar Link pending
gcxqceod4dzq000004.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending